Phenylpropanolamine
Phenylpropanolamine (PPA) is a non-selective sympathomimetic amine primarily used in veterinary medicine to manage **urinary incontinence** associated with urethral sphincter mechanism incompetence (USMI), particularly in spayed female dogs. While it has historically been used as a nasal decongestant, its principal veterinary indication relies on its ability to increase smooth muscle tone in the bladder neck and proximal urethra. **Clinical Pearls:** * PPA is highly effective for acquired urinary incontinence in dogs, with success rates often exceeding 75-85%. * Because it is a sympathomimetic, it can cause systemic adrenergic effects, most notably hypertension and behavioral changes (restlessness, anxiety). * It is classified as a List 1 chemical in the USA due to its potential use as a precursor in methamphetamine synthesis, which may subject it to specific purchasing restrictions.
Mecanismo: Phenylpropanolamine acts primarily as an **indirect-acting sympathomimetic**, though it may have some direct receptor agonist activity. * **Mechanism:** It stimulates the release of endogenous **norepinephrine** from presynaptic nerve terminals. * **Pathway:** Released norepinephrine binds to **alpha-1 adrenergic receptors** located in the smooth muscle of the internal urethral sphincter and bladder neck → **increased sphincter tone** → prevention of urine leakage. * It also stimulates beta-adrenergic receptors, which can contribute to systemic cardiovascular effects (e.g., increased heart rate and contractility). * **Note:** Prolonged use or excessive dosing frequency can theoretically deplete norepinephrine from storage sites, leading to tachyphylaxis (decreased response), though this is rarely documented in dogs or cats treated for incontinence.
Dosificación por especie
- Urethral sphincter hypotonus · 12.5 mg PO q8h · PO · q8h
- Urethral sphincter hypotonus · 1-1.5 mg/kg PO q8h · PO · q8h
- Urethral sphincter hypotonus · 1.1 -2.2 mg/kg PO two to three times daily · PO · q8-12h
- Urethral sphincter hypotonus · 12.5-50 mg (total dose) or 1-2 mg/kg PO q8h · PO · q8h
- Urethral sphincter hypotonus · Dogs weighing less than 40 lbs: ½ capsule PO daily. Dogs 40-100 lbs: 1 capsule PO daily. Dogs weighing >100 lbs: 1.5 capsules PO per day. · PO · q24h · Using the time-release 75 mg capsules
- Urethral sphincter hypotonus · 1-1.5 mg/kg PO two to three times a day · PO · q8-12h · Controls 74-92% of dogs with primary sphincter mechanism incontinence. Over half of dogs not responding to regular PPA will respond to sustained-release PPA.
- Urethral sphincter hypotonus · 5-50 mg per dog PO q8h or 1.5 mg/kg PO q8h-12h · PO · q8-12h
- Retrograde ejaculation · 3-4 mg/kg PO twice daily · PO · q12h · May be tried
Las dosis son una referencia clínica para médicos veterinarios. Confirme siempre con la información vigente del producto y el paciente individual.
Vías de administración
Contraindicaciones
- Glaucoma
- Prostatic hypertrophy
- Hyperthyroidism
- Diabetes mellitus
- Cardiovascular disorders
- Hypertension
- Severe renal or hepatic disease
Efectos adversos
- Restlessness
- Anxiety
- Irritability
- Urine retention
- Tachycardia
- Hypertension
- Anorexia
- Rare reports of 'stroke' in dogs
- Panting
Interacciones farmacológicas
- Halothane · Increased risk of arrhythmias. Propranolol may be administered should these occur. · major
- Monoamine Oxidase (MAO) Inhibitors (e.g., amitraz, selegiline) · Should not be given within two weeks of receiving MAOIs due to risk of severe hypertension and toxicity.
- NSAIDs (including aspirin) · Increased chance of hypertension if given concomitantly.
- Reserpine · Increased chance of hypertension if given concomitantly.
- Other Sympathomimetic Agents (e.g., ephedrine) · Should not be administered together as increased toxicity may result.
- Tricyclic Antidepressants (e.g., clomipramine, amitriptyline) · Increased chance of hypertension if given concomitantly.
- NSAIDs · Increased risk of hypertension · moderate
- Monoamine Oxidase Inhibitors (MAOIs) · Risk of severe hypertensive crisis · major
- Tricyclic Antidepressants · Increased sympathomimetic effects and risk of hypertension · major
Monitoreo
- Clinical effectiveness (reduction in urine leakage)
- Adverse effects (restlessness, irritability, anorexia)
- Blood pressure
- Clinical response (reduction in urinary incontinence)
- Heart rate and rhythm
- Behavioral changes (restlessness, pacing)
Sobredosis
Clinical signs of overdosage may consist of an exacerbation of adverse effects (restlessness, anxiety). **Severe Overdose Signs:** * **Cardiovascular:** Hypertension to rebound hypotension, bradycardias to tachycardias, and cardiovascular collapse. * **CNS:** Stimulation progressing to coma. * *Case report:* A dog ingesting 48 mg/kg developed ventricular tachycardia and myocardial necrosis (resolved within 6 months). **Treatment:** * If recent, empty the stomach using usual precautions and administer charcoal and a cathartic. * Treat clinical signs supportively. * > **WARNING:** Do NOT use propranolol to treat hypertension in bradycardic patients. Do NOT use atropine to treat bradycardia. * Hypertension may be managed with a phenothiazine (e.g., acepromazine at very low doses such as 0.02 mg/kg IV or IM). If unsuccessful, consider a CRI of nitroprusside. * Contact an animal poison control center for further guidance.
La referencia de fármacos de VetSheet está destinada a médicos veterinarios como apoyo a la decisión clínica; no sustituye el juicio profesional ni la información vigente del fabricante.